IBDEI0O0 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10681,1,3,0)
 ;;=3^Eye/Vision Exam w/o Abnormal Findings
 ;;^UTILITY(U,$J,358.3,10681,1,4,0)
 ;;=4^Z01.00
 ;;^UTILITY(U,$J,358.3,10681,2)
 ;;=^5062612
 ;;^UTILITY(U,$J,358.3,10682,0)
 ;;=Z01.01^^74^689^6
 ;;^UTILITY(U,$J,358.3,10682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10682,1,3,0)
 ;;=3^Eye/Vision Exam w/ Abnormal Findings
 ;;^UTILITY(U,$J,358.3,10682,1,4,0)
 ;;=4^Z01.01
 ;;^UTILITY(U,$J,358.3,10682,2)
 ;;=^5062613
 ;;^UTILITY(U,$J,358.3,10683,0)
 ;;=I10.^^74^689^9
 ;;^UTILITY(U,$J,358.3,10683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10683,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,10683,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,10683,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,10684,0)
 ;;=Z21.^^74^689^10
 ;;^UTILITY(U,$J,358.3,10684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10684,1,3,0)
 ;;=3^Asymptomatic HIV Infection Status
 ;;^UTILITY(U,$J,358.3,10684,1,4,0)
 ;;=4^Z21.
 ;;^UTILITY(U,$J,358.3,10684,2)
 ;;=^5062777
 ;;^UTILITY(U,$J,358.3,10685,0)
 ;;=Z01.021^^74^689^7
 ;;^UTILITY(U,$J,358.3,10685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10685,1,3,0)
 ;;=3^Eye/Vision Exam After Failed Exam w/ Abnormal Findings 
 ;;^UTILITY(U,$J,358.3,10685,1,4,0)
 ;;=4^Z01.021
 ;;^UTILITY(U,$J,358.3,10685,2)
 ;;=^5158319
 ;;^UTILITY(U,$J,358.3,10686,0)
 ;;=Z01.020^^74^689^8
 ;;^UTILITY(U,$J,358.3,10686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10686,1,3,0)
 ;;=3^Eye/Vision Exam After Failed Exam w/o Abnormal Findings
 ;;^UTILITY(U,$J,358.3,10686,1,4,0)
 ;;=4^Z01.020
 ;;^UTILITY(U,$J,358.3,10686,2)
 ;;=^5158318
 ;;^UTILITY(U,$J,358.3,10687,0)
 ;;=Z82.1^^74^689^11
 ;;^UTILITY(U,$J,358.3,10687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10687,1,3,0)
 ;;=3^Family Hx Blindness/Visual Loss
 ;;^UTILITY(U,$J,358.3,10687,1,4,0)
 ;;=4^Z82.1
 ;;^UTILITY(U,$J,358.3,10687,2)
 ;;=^5063365
 ;;^UTILITY(U,$J,358.3,10688,0)
 ;;=Z83.518^^74^689^12
 ;;^UTILITY(U,$J,358.3,10688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10688,1,3,0)
 ;;=3^Family Hx Other Eye Disorder
 ;;^UTILITY(U,$J,358.3,10688,1,4,0)
 ;;=4^Z83.518
 ;;^UTILITY(U,$J,358.3,10688,2)
 ;;=^5063383
 ;;^UTILITY(U,$J,358.3,10689,0)
 ;;=Z83.511^^74^689^13
 ;;^UTILITY(U,$J,358.3,10689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10689,1,3,0)
 ;;=3^Family Hx of Glaucoma
 ;;^UTILITY(U,$J,358.3,10689,1,4,0)
 ;;=4^Z83.511
 ;;^UTILITY(U,$J,358.3,10689,2)
 ;;=^5063382
 ;;^UTILITY(U,$J,358.3,10690,0)
 ;;=H35.3211^^74^690^1
 ;;^UTILITY(U,$J,358.3,10690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10690,1,3,0)
 ;;=3^Exudative AMD,RIGHT eye,active CNV
 ;;^UTILITY(U,$J,358.3,10690,1,4,0)
 ;;=4^H35.3211
 ;;^UTILITY(U,$J,358.3,10690,2)
 ;;=^5138521
 ;;^UTILITY(U,$J,358.3,10691,0)
 ;;=H35.3221^^74^690^2
 ;;^UTILITY(U,$J,358.3,10691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10691,1,3,0)
 ;;=3^Exudative AMD,LEFT eye,active CNV 
 ;;^UTILITY(U,$J,358.3,10691,1,4,0)
 ;;=4^H35.3221
 ;;^UTILITY(U,$J,358.3,10691,2)
 ;;=^5138525
 ;;^UTILITY(U,$J,358.3,10692,0)
 ;;=H35.059^^74^690^3
 ;;^UTILITY(U,$J,358.3,10692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10692,1,3,0)
 ;;=3^Retinal CNV or NV,unspec          
 ;;^UTILITY(U,$J,358.3,10692,1,4,0)
 ;;=4^H35.059
 ;;^UTILITY(U,$J,358.3,10692,2)
 ;;=^5005601
 ;;^UTILITY(U,$J,358.3,10693,0)
 ;;=H35.82^^74^690^4
 ;;^UTILITY(U,$J,358.3,10693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10693,1,3,0)
 ;;=3^Retinal Ischemia,unspec           
